Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
text
Tags
clinical trials
life sciences
national blog main
boston blog main
boston top stories
drugs
fda
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
alnylam pharmaceuticals
aminolevulinic acid
arena pharmaceuticals
biotech
bitcoin
boston
boulder/denver blog main
boulder/denver top stories
cancer
cannabidiol
cardiovascular disease
colorectal cancer
daraprim
detroit blog main
detroit top stories
dravet syndrome
eisai
epidiolex
europe blog main
europe top stories
fen-phen
fenfluramine
givosiran
gw pharmaceuticals
indiana blog main
indiana top stories
lennox-gastaut syndrome
lorcaserin
lung cancer
What
drug
4
×
market
4
×
medicine
4
×
data
fda
pharmaceuticals
weeks
ago
alnylam
approved
available
battle
brazil
cancer
cannabis
cleared
combat
company
daraprim
decision
derivative
developed
eisai
epilepsy
essential
far
flags
form
gw
gw’s
health
higher
import
incidence
increase
interference
list
lorcaserin
loss
malaria
Language
unset
Current search:
market
×
medicine
×
drug
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@cryptocoinsnews.com
8 years ago
This Company Said They'd Import Daraprim From Brazil For $10 Then Vanished